報價延遲最少15分鐘:2024/12/23 22:29 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-100.39/-0.42
|
|
企業價值
78.57M
|
| 資產負債 |
|
每股賬面淨值
0.77
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
22.77M
|
|
每股收益
0.67
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:29 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment. |